Neurocrine Biosciences filed reports with the SEC on August 16, 2026.

The entities involved

• Neurocrine Biosciences →

  American biopharmaceutical company

  Nothing else this week.

• SEC →

  Slovak company

  • DHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Mon 17:57
  • The Fidelis Partnership is incorporating in Bermuda and filing for an initial public offering on the NYSE, with principal offices in London and a main office in Dublin.Mon 17:12

Related events

• Nxera Pharma has acquired rights to NBI-’567 through Neurocrine Biosciences, with the goal of improving patient outcomes in Japan.Aug 26
• TransMedics Group, Inc. filed required reports with the SEC on August 27, 2026.Aug 27